幽門螺旋桿菌感染已知是消化性潰瘍、非賁門胃癌和胃黏膜相關淋巴淋巴瘤的危險因子，其也與一些胃外表現的風險增加有關，例如心血管、神經、血液和代謝疾病。本研究旨在瞭解瞭解研究對象的人口學變項以及幽門螺旋桿菌感染之現況。探討社會人口學與幽門螺旋桿菌、代謝症候群、代謝功能障礙相關脂肪性肝病及肝纖維化之差異及相關性。
本研究為觀察性橫斷面研究，蒐集台灣北部某區域教學醫院健康檢查中心資料，自2021年9月至2024年8月為期三年的時間，共有2343位接受自費健康檢查的民眾。並以獨立樣本t 檢定、卡方檢定、羅吉斯回歸和線性迴歸進行統計分析。
本研究發現，在幽門螺旋桿菌感染者中，50-59 歲年齡層比例最高。共病分析顯示，幽門螺旋桿菌感染與代謝症候群及糖尿病呈顯著正相關。特別是幽門螺旋桿菌感染與代謝症候群之間的關聯性更為顯著（勝算比 [Odds Ratio] = 1.810，95% 信賴區間 [CI]: 1.229–2.665，p = 0.003）。然而，幽門螺旋桿菌感染與其他代謝相關疾病（如肥胖、脂肪肝、MASLD 及肝纖維化）的關聯性未達統計顯著性。研究結果指出，幽門螺旋桿菌感染可能是代謝症候群的一項重要風險因子。另一方面，脂肪肝與男性、ALT 指數及胰島素阻抗呈較高相關性，而肝纖維化則與年齡及 B 型肝炎較為相關。
基於上述結果，建議未來應針對 50-59 歲高風險族群進行篩查與早期介入，並評估其代謝症候群風險，以便及早進行干預。此外，建議增加代謝症候群及糖尿病患者的胃鏡檢查篩檢率。同時，未來研究可進一步比較同一批幽門螺旋桿菌感染者在接受根除治療之後的差異，並分析根除治療的時間點（較早或較晚除菌）對代謝相關疾病的影響，為制定精準干預策略提供更多依據。

Helicobacter pylori infection is known to be a risk factor for peptic ulcer, non-cardia gastric cancer, and mucosa-associated lymphoid tissue lymphoma. It is also associated with an increased risk of various extragastric manifestations, including cardiovascular, neurological, hematological, and metabolic diseases. This study aims to investigate the demographic characteristics of the study population and the prevalence of H. pylori infection. It further explores the differences and correlations between socio-demographic factors, H. pylori infection, metabolic syndrome (MetS), metabolic-associated fatty liver disease (MASLD), and liver fibrosis.
This cross-sectional study analyzed data from 2,343 individuals who underwent voluntary health checkups at a teaching hospital in northern Taiwan from September 2021 to August 2024. Independent sample t-test, chi-square test, logistic regression, and linear regression were used for statistical analysis.
The results showed that the prevalence of H. pylori infection was highest among individuals aged 50-59 years. H. pylori infection was positively associated with metabolic syndrome and diabetes. More importantly, H. pylori infection was significantly associated with metabolic syndrome (Odds Ratio = 1.810, 95% CI: 1.229-2.665, p = 0.003). However, no significant association was found with other metabolic diseases such as obesity and metabolic-associated fatty liver disease (MASLD), and liver fibrosis. The study results indicate that Helicobacter pylori infection may be an important risk factor for metabolic syndrome. On the other hand, fatty liver is more strongly associated with male gender, ALT levels, and insulin resistance, while liver fibrosis is more significantly related to age and hepatitis B.
Future studies should focus on screening and interventions for high-risk populations, particularly those aged 50-59 years, and assess their risk for metabolic syndrome. Additionally, increasing endoscopy screening rates for individuals with metabolic syndrome and diabetes is recommended. Further studies comparing individuals with and without H. pylori infection, as well as those who underwent early or late eradication therapy, could provide more insights into the long-term effects of H. pylori infection and inform public health strategies.

一、 中文文獻
中華民國內分泌暨糖尿病學會(2022)。2022糖尿病臨床照護指引。作者。
衛生福利部國民健康署（2015，11月02日），成人（20歲以上）代謝症候群之判定標準(2007 台灣)，取自https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=639&pid=1219
衛生福利部國民健康署（2022，6月30日），110年國人死因統計結果，取自https://www.mohw.gov.tw/cp-16-70314-1.html
衛生福利部國民健康署 (2022，5 月 9 日)，國民營養健康狀況變遷調查成果報告2017-2020年。取自https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=3999&pid=15562
李熹昌、吳明賢(2006)。年齡及性別與胃癌臨床病理特徵之相關性。北市醫學雜誌，3(6)，542-553。
周玉民(2004)。幽門螺旋桿菌家庭傳染：應用流行感染世代鏈模式分析馬祖2186名居民〔未出版之碩士論文〕。國立臺灣大學預防醫學研究所。
柯秉宏、許景盛(2023)。代謝相關性脂肪肝病的診斷與治療。臺灣醫界，66(3)，12-18。
劉志銘(2019)。國內幽門螺旋桿菌感染流行病學及抗藥性分析研究計畫。衛生福利部疾病管制署108年委託科技研究計畫成果報告。告(計畫編號：MOHW108-CDC-C-114-112102)。衛生福利部疾病管制署。
鄭嘉琪(2008)。臺灣五區域幽門螺旋桿菌血清流行病學研究及水中幽門螺旋桿菌之偵測〔未出版之碩士論文〕。國立臺灣大學臨床醫學研究所。
二、 英文文獻
Abdel‐Razik, A., Mousa, N., Shabana, W., Refaey, M., Elhelaly, R., Elzehery, R., Abdelsalam, M., Elgamal, A., Nassar, M. R., El-Soud, A. A., Seif, A. S., Tawfik, A. M., El-Wakeel, N., & Eldars, W. (2018). Helicobacter pylori and non‐alcoholic fatty liver disease: A new enigma?. Helicobacter, 23(6), e12537. https://doi.org/10.1111/hel.12537
Ackermann, R. T., Finch, E. A., Brizendine, E., Zhou, H., & Marrero, D. G.(2008). Translating the Diabetes Prevention Program into the community: the DEPLOY pilot study. American journal of preventive medicine, 35(4), 357-363. https://doi.org/10.1016/j.amepre.2008.06.035
Alberti, K. G. M. M.,& Zimmet, P.Z.(1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic medicine, 15(7), 539-553.
https://doi.org/10.1002/(SICI)1096-9136(199807)15:7%3C539::AID-DIA668%3E3.0.CO;2-S
Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart,J.C., James, W.P.T., Loria,C.M., & Smith Jr, S. C.(2009). Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation, 120(16), 1640-1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
American Diabetes Association. (2020). 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes care, 43(Supplement_1), S14-S31.https://doi.org/10.2337/dc20-S002
Azami, M., Baradaran, H. R., Dehghanbanadaki, H., Kohnepoushi, P., Saed, L., Moradkhani, A., Moradpour,F., & Moradi, Y. (2021). Association of Helicobacter pylori infection with the risk of metabolic syndrome and insulin resistance: an updated systematic review and meta-analysis. Diabetology & metabolic syndrome, 13(1), 145.https://doi.org/10.1186/s13098-021-00765-x
Baeg, M. K., Yoon, S. K., Ko, S. H., Noh, Y. S., Lee, I. S., & Choi, M. G. (2016). Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. World journal of gastroenterology, 22(8), 2592–2600. https://doi.org/10.3748%2Fwjg.v22.i8.2592
Baj, J., Forma, A., Sitarz, M., Portincasa, P., Garruti, G., Krasowska, D., & Maciejewski, R. (2020). Helicobacter pylori virulence factors—mechanisms of bacterial pathogenicity in the gastric microenvironment. Cells, 10(1), 27. https://doi.org/10.3390/cells10010027
Baj, J., Forma, A., Flieger, W., Morawska, I., Michalski, A., Buszewicz, G., Sitarz, E., Portincasa, P., Garruti, G., Flieger, M., & Teresiński, G. (2021). Helicobacter pylori infection and extragastric diseases—a focus on the central nervous system. Cells, 10(9), 2191. https://doi.org/10.3390/cells10092191
Bartels, L. E., Pedersen, A. B., Kristensen, N. R., Jepsen, P., Vilstrup, H., Stengaard-Pedersen, K., & Dahlerup, J. F. (2019). Helicobacter pylori infection is not associated with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 48(1), 24-31. https://doi.org/10.1080/03009742.2018.1464205
Blaser, M. J. (1992). Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology, 102(2), 720-727.
Bonora, E., Kiechl, S., Willeit, J., Oberhollenzer, F., Egger, G., Targher, G., Alberiche, M., Bonadonna, R.C.,& Muggeo, M. (1998). Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes, 47(10), 1643-1649.https://doi.org/10.2337/diabetes.47.10.1643
Bowen, M. E., Schmittdiel, J. A., Kullgren, J. T., Ackermann, R. T., & O’Brien, M. J. (2018). Building toward a population-based approach to diabetes screening and prevention for US adults. Current diabetes reports, 18,104. https://doi.org/10.1007/s11892-018-1090-5
Cárdenas, V. M., Boller, F., & Román, G. C. (2019). Helicobacter pylori, vascular risk factors and cognition in US older adults. Brain Sciences, 9(12), 370. https://doi.org/10.3390/brainsci9120370
Chen, Y. Y., Fang, W. H., Wang, C. C., Kao, T. W., Chang, Y. W., Wu, C. J., Zhou, Y. C., Sun,Y.S., & Chen, W. L. (2019). Helicobacter pylori infection increases risk of incident metabolic syndrome and diabetes: a cohort study. PloS ONE, 14(2), e0208913.https://doi.org/10.1371/journal.pone.0208913
Choi, J. M., Lim, S. H., Han, Y. M., Lee, H., Seo, J. Y., Park, H. E., Kwak, M. S., Chung, G. E., Choi, S. Y., & Kim, J. S. (2019). Association between Helicobacter pylori infection and arterial stiffness: Results from a large cross-sectional study. PloS one, 14(8), e0221643. https://doi.org/10.1371/journal.pone.0221643
Colberg, S. R., Sigal, R. J., Fernhall, B., Regensteiner, J. G., Blissmer, B. J., Rubin, R. R., Chasan-Taber L., Albright AL.,＆Braun B. (2010). Exercise and type 2 diabetes: The American College of Sports Medicine and the American Diabetes Association: Joint position statement. Diabetes Care, 33(12), e147-e167. https://doi.org/10.2337/dc10-9990
Crowe, S. E. (2019). Helicobacter pylori infection. New England Journal of Medicine, 380(12), 1158-1165. DOI: 10.1056/NEJMcp1710945
Dai, X., Zhai, L., Chen, Q., Miller, J. D., Lu, L., Hsue, C., Liu, L., Yuan, X., Wei, W., Ma, X., Fang, Z., Zhao, W., Liu, Y., Huang, F.,& Lou,Q. (2019). Two‐year‐supervised resistance training prevented diabetes incidence in people with prediabetes: A randomised control trial. Diabetes/metabolism research and reviews, 35(5), e3143.https://doi.org/10.1002/dmrr.3143
Devaraj, S., Rosenson, R. S., & Jialal, I. (2004). Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinology and Metabolism Clinics, 33(2), 431-453.https://doi.org/10.1016/j.ecl.2004.03.008
Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England journal of medicine, 346(6), 393-403. https://psycnet.apa.org/doi/10.1056/NEJMoa012512
Doğan, Z., Filik, L., Ergül, B., Sarikaya, M., & Akbal, E. (2013). Association between Helicobacter pylori and liver-to-spleen ratio: a randomized-controlled single-blind study. European Journal of Gastroenterology & Hepatology, 25(1), 107-110. DOI: 10.1097/MEG.0b013e3283590c10
Ebrahimi, A., Soofizadeh, B., Ebrahimi, F., Moaadab, S. Y., Bonyadi, M., Gojazadeh, M., & Mahdavi, A. M. (2019). Relationship between Helicobacter pylori cytotoxin-associated gene A protein with clinical outcomes in patients with rheumatoid arthritis. Immunology Letters, 211, 49-52.https://doi.org/10.1016/j.imlet.2019.05.014
Etchegaray-Morales, I., Jiménez-Herrera, E. A., Mendoza-Pinto, C., Rojas-Villarraga, A., Macías-Díaz, S., Osorio-Peña, Á. D., Munguía-Realpozo, P., & García-Carrasco, M. (2021). Helicobacter pylori and its association with autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis and Sjögren syndrome. Journal of Translational Autoimmunity, 4, 100135.https://doi.org/10.1016/j.jtauto.2021.100135
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wong, V. W.S., Dufour, J.F., Schattenberg, J.M., Kawaguchi, T., Arrese ,M., Arrese, L., Shih, G., Tiribelli, C., Yki-Järvinen, H., Fan, J.G., Grønbæk, H., Yilmaz, Y.,...,George, J.(2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of hepatology,73(1), 202-209.https://doi.org/10.1016/j.jhep.2020.03.039
Fang, Y., Fan, C., & Xie, H. (2019). Effect of Helicobacter pylori infection on the risk of acute coronary syndrome: A systematic review and meta-analysis. Medicine, 98(50), e18348. DOI：10.1097/MD.0000000000018348
Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., & Assi, H. I. (2022). Metabolic syndrome: updates on pathophysiology and management in 2021. International journal of molecular sciences, 23(2), 786. https://doi.org/10.3390/ijms23020786
Farrell, G. C., Chitturi, S., Lau, G. K., Sollano, J. D., & Asia–Pacific Working Party on NAFLD.(2007). Guidelines for the assessment and management of non‐alcoholic fatty liver disease in the Asia–Pacific region: Executive summary. Journal of gastroenterology and hepatology, 22(6), 775-777. https://doi.org/10.1111/j.1440-1746.2007.05002.x
Fu, P., Gao, M., & Yung, K. K. L. (2019). Association of intestinal disorders with Parkinson’s disease and Alzheimer’s disease: a systematic review and meta-analysis. ACS chemical neuroscience, 11(3), 395-405. https://doi.org/10.1021/acschemneuro.9b00607
Gasbarrini, A., Franceschi, F., Tartaglione, R., Landolfi, R., Pola, P., & Gasbarrini, G. (1998). Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. The Lancet, 352(9131), 878. https://doi.org/10.1016/S0140-6736(05)60004-9
Gebel, J., Vacata, V., Sigler, K., Pietsch, H., Rechenburg, A., Exner, M., & Kistemann, T. (2001). Disinfectant activity against different morphological forms of Helicobacter pylori: first results. Journal of Hospital Infection, 48, S58-S63. https://doi.org/10.1016/S0195-6701(01)90016-7
Gill, P., Alvandi, A. H., Abdul-Tehrani, H., & Sadeghizadeh, M. (2008). Colorimetric detection of Helicobacter pylori DNA using isothermal helicase-dependent amplification and gold nanoparticle probes. Diagnostic microbiology and infectious disease, 62(2), 119-124. https://doi.org/10.1016/j.diagmicrobio.2008.05.003
Gofton, C., Upendran, Y., Zheng, M. H., & George, J. (2023). MAFLD: How is it different from NAFLD?. Clinical and molecular hepatology, 29(Suppl), S17–S31. https://doi.org/10.3350%2Fcmh.2022.0367
González-González, J. G., Violante-Cumpa, J. R., Zambrano-Lucio, M., Burciaga-Jimenez, E., Castillo-Morales, P. L., Garcia-Campa, M., Solis R. C., González-Colmenero, A.D., & Rodríguez-Gutiérrez, R. (2022). HOMA-IR as a predictor of health outcomes in patients with metabolic risk factors: a systematic review and meta-analysis. High Blood Pressure & Cardiovascular Prevention, 29(6), 547-564. https://doi.org/10.1007/s40292-022-00542-5
Goodwin, C. S., Mendall, M. M., & Northfield, T. C. (1997). Helicobacter pylori infection. The Lancet, 349(9047), 265-269. https://doi.org/10.1016/S0140-6736(96)07023-7
Gravina, A. G., Priadko, K., Ciamarra, P., Granata, L., Facchiano, A., Miranda, A., Dallio, M., Federico, A., & Romano, M. (2020). Extra-gastric manifestations of Helicobacter pylori infection. Journal of clinical medicine, 9(12), 3887. https://doi.org/10.3390/jcm9123887
Hagström, H., Vessby, J., Ekstedt, M., & Shang, Y. (2024). 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. Journal of hepatology, 80(2), e76-e77. https://doi.org/10.1016/j.jhep.2023.08.026
He, J., Liu, Y., Ouyang, Q., Li, R., Li, J., Chen, W., Hu, W., He, L., Bao, Q., Li, P., & Hu, C. (2022). Helicobacter pylori and unignorable extragastric diseases: Mechanism and implications. Frontiers in microbiology, 13, 972777. https://doi.org/10.3389/fmicb.2022.972777
Hou, Y., Sun, W., Zhang, C., Wang, T., Guo, X., Wu, L., Qin, L., & Liu, T. (2017). Meta-analysis of the correlation between Helicobacter pylori infection and autoimmune thyroid diseases. Oncotarget, 8(70), 115691-115700. doi:10.18632/oncotarget.22929
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. (1994). Infection with Helicobacter pylori. In Schistosomes, liver flukes and Helicobacter pylori. International Agency for Research on Cancer. https://www.ncbi.nlm.nih.gov/books/NBK487794/
Jiang, D., Chen, C., Liu, X., Huang, C., Yan, D., Zhang, X., Zhou, Y., Lin, Y., Zhou, Y., Guan, Z., Ding, C., Lan, L., Zhu, C., Wu, J., Li, L.,& Yang, S. (2021). Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis. Annals of Translational Medicine, 9(23), 1718.
https://doi.org/10.21037%2Fatm-21-3052
Kaptan, K., Beyan, C., Ural, A. U., Cetin, T., Avcu, F., Gülşen, M., Finci, R., & Yalçín, A. (2000). Helicobacter pylori—is it a novel causative agent in vitamin B12 deficiency?. Archives of Internal Medicine, 160(9), 1349-1353. doi:10.1001/archinte.160.9.1349
Kim, B. J., Kim, H. S., Jang, H. J., & Kim, J. H. (2018). Helicobacter pylori eradication in idiopathic thrombocytopenic purpura: a meta‐analysis of randomized trials. Gastroenterology research and practice, 2018(1), 6090878. https://doi.org/10.1155/2018/6090878
Kim, J. W., Kim, T. J., Kim, J. E., Na, J. E., Lee, H., Min, B. H., Lee, J. H., Rhee, P. L., & Kim, J. J. (2022). Impact of Helicobacter pylori eradication on the risk of incident nonalcoholic fatty liver disease: a cohort study. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 22(2), 131-138. https://doi.org/10.7704/kjhugr.2021.0060
Kim, T. J., Sinn, D. H., Min, Y. W., Son, H. J., Kim, J. J., Chang, Y., Baek, S. Y., Ahn, S. H., Lee, H., & Ryu, S. (2017). A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease. Journal of gastroenterology, 52, 1201-1210. https://doi.org/10.1007/s00535-017-1337-y
Kusters, J. G., Van Vliet, A. H., & Kuipers, E. J. (2006). Pathogenesis of Helicobacter pylori infection. Clinical microbiology reviews, 19(3), 449-490. https://doi.org/10.1128/cmr.00054-05
Lai, C. Y., Yang, T. Y., Lin, C. L., & Kao, C. H. (2015). Helicobacter pylori infection and the risk of acute coronary syndrome: a nationwide retrospective cohort study. European Journal of Clinical Microbiology & Infectious Diseases, 34, 69-74. https://doi.org/10.1007/s10096-014-2207-7
Lee, Y. C., Dore, M. P., & Graham, D. Y. (2022). Diagnosis and treatment of Helicobacter pylori infection. Annual review of medicine, 73, 183-195. https://doi.org/10.1146/annurev-med-042220-020814
Li, N., Liu, S. F., Dong, K., Zhang, G. C., Huang, J., Wang, Z. H., & Wang, T. J. (2019). Exosome-transmitted miR-25 induced by H. pylori promotes vascular endothelial cell injury by targeting KLF2. Frontiers in cellular and infection microbiology, 9, 366. https://doi.org/10.3389/fcimb.2019.00366
Lim, S. H., Kim, N., Kwon, J. W., Kim, S. E., Baik, G. H., Lee, J. Y., Park, K. S., Shin, J. E., Song, H. J., Myung, D-S., Choi, S. C., Kim, H. J., Lim, J. H., Yim, J. Y., & Kim, J. S. (2019). Positive association between Helicobacter pylori infection and metabolic syndrome in a Korean population: a multicenter nationwide study. Digestive diseases and sciences, 64, 2219-2230. https://doi.org/10.1007/s10620-019-05544-3
Lin, J. T., Wang, J. T., Wang, T. H., Wu, M. S., Lee, T. K., & Chen, C. J. (1993). Helicobacter pylori infection in a randomly selected population, healthy volunteers, and patients with gastric ulcer and gastric adenocarcinoma: a seroprevalence study in Taiwan. Scandinavian journal of gastroenterology, 28(12), 1067-1072. https://doi.org/10.3109/00365529309098311
Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J.(2006). Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. The Lancet, 368(9548), 1673-1679. https://doi.org/10.1016/S0140-6736(06)69701-8
Liou, J. M., Malfertheiner, P., Lee, Y. C., Sheu, B. S., Sugano, K., Cheng, H. C., Yeoh,K. G., Hsu1, P.I., Goh, K.L., Mahachai, V., Gotoda, T., Chang, W. L., Chen, M.J., Chiang, T. H., Chen1,C.C., Wu, C.Y., Leow, A.H.R., Chen1, J.Y.W., Wu, D. C.,...,El-Omar, E. M. (2020). Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut, 69(12), 2093-2112. https://doi.org/10.1136/gutjnl-2020-322368
Liu, Y., Shuai, P., Chen, W., Liu, Y., & Li, D. (2023). Association between Helicobacter pylori infection and metabolic syndrome and its components. Frontiers in Endocrinology, 14, 1188487. https://doi.org/10.3389/fendo.2023.1188487
Ludwig, J., Viggiano, T. R., Mcgill, D. B., & Oh, B. (1980). Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. In Mayo Clinic Proceedings, 55(7), 434-438. https://orcid.org/0000-0002-3726-7230
Maharshi, V., Gupta, P., Kumar, V. L., Upadhyay, A. D., Das, P., Yadav, R., Nayak, B., Kumar, R., & Shalimar. (2020). Effect of Helicobacter pylori-eradication therapy on hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomized–controlled pilot study. Gastroenterology report, 8(2), 104-110. https://doi.org/10.1093/gastro/goz058
Malfertheiner, P., Camargo, M. C., El-Omar, E., Liou, J. M., Peek, R., Schulz, C., Smith,S.I., & Suerbaum, S. (2023). Helicobacter pylori infection. Nature reviews Disease primers, 9(1), 19. https://doi.org/10.1038/s41572-023-00431-8
Mansour, L., El-Kalla, F., Kobtan, A., Abd-Elsalam, S., Yousef, M., Soliman, S., Ali, L. A., Elkhalawany, W., Amer, I., Harras, H., Hagras, M. M., & Elhendawy, M. (2018). Helicobacter pylori may be an initiating factor in newly diagnosed ulcerative colitis patients: a pilot study. World journal of clinical cases, 6(13), 641-649. https://doi.org/10.23750%2Fabm.v89i9-S.7878
Mantovani, A., Lando, M. G., Borella, N., Scoccia, E., Pecoraro, B., Gobbi, F., Bisoffi, Z., Valenti, L., Tilg, H., Byrne, M.G., & Targher, G. (2024). Relationship between Helicobacter pylori infection and risk of metabolic dysfunction‐associated steatotic liver disease: An updated meta‐analysis. Liver International,44(7),1513-1525. https://doi.org/10.1111/liv.15925
Marshall, B., & Warren, J. R. (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The lancet, 323(8390), 1311-1315. https://doi.org/10.1016/S0140-6736(84)91816-6
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. (1985). Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419. https://doi.org/10.1007/BF00280883
Mendall, M. A., Goggin, P. M., Molineaux, N., Levy, J., Toosy, T., Strachan, D., ... & Northfield, T. C. (1994). Relation of Helicobacter pylori infection and coronary heart disease. Heart, 71(5), 437-439. https://doi.org/10.1136/hrt.71.5.437
Miao, L., Targher, G., Byrne, C. D., Cao, Y. Y., & Zheng, M. H. (2024). Current status and future trends of the global burden of MASLD. Trends in Endocrinology & Metabolism,35(8), 697-707.https://doi.org/10.1016/j.tem.2024.02.007
Nejati, S., Karkhah, A., Darvish, H., Validi, M., Ebrahimpour, S., & Nouri, H. R. (2018). Influence of Helicobacter pylori virulence factors CagA and VacA on pathogenesis of gastrointestinal disorders. Microbial pathogenesis, 117, 43-48. https://doi.org/10.1016/j.micpath.2018.02.016
Newsome, P. N., Sasso, M., Deeks, J. J., Paredes, A., Boursier, J., Chan, W. K., Yilmaz, Y., Czernichow, S., Zheng, M.H., Wong, V.W.S., Allison, M., Tsochatzis, E., Anstee, Q.M., Sheridan, D.A., Eddowes, P.J., Guha, I.N., Cobbold, J.F., Paradis, V., Bedossa, P., …,Harrison, S. A. (2020). FibroScan-AST (FASL.,T) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. The lancet Gastroenterology & hepatology, 5(4), 362-373. https://doi.org/10.1016/S2468-1253(19)30383-8
Nilsson, P. M., Tuomilehto, J., & Rydén, L. (2019). The metabolic syndrome–What is it and how should it be managed?. European journal of preventive cardiology, 26(2_suppl), 33-46.https://doi.org/10.1177/2047487319886404
Noubiap, J. J., Nansseu, J. R., Lontchi-Yimagou, E., Nkeck, J. R., Nyaga, U. F., Ngouo, A. T., Tounouga, D. E., Tianyi, F.L., Foka, A. J., Ndoadoumgue, A. L.,& Bigna, J. J. (2022). Geographic distribution of metabolic syndrome and its components in the general adult population: A meta-analysis of global data from 28 million individuals. Diabetes research and clinical practice, 188, 109924.https://doi.org/10.1016/j.diabres.2022.109924
Okushin, K., Takahashi, Y., Yamamichi, N., Shimamoto, T., Enooku, K., Fujinaga, H., Tsutsumi, T., Shintani, Y., Sakaguchi,Y., Ono, S., Kodashima, S., Fujishiro, M., Moriya, K., Yotsuyanagi, H., Mitsushima, T & Koike, K. (2015). Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. BMC gastroenterology, 15(25), 1-10. https://doi.org/10.1186/s12876-015-0247-9
Ossei-Gerning, N., Moayyedi, P., Smith, S., Braunholtz, D., Wilson, J. I., Axon, A. T. R., & Grant, P. J. (1997). Helicobacter pylori infection is related to atheroma in patients undergoing coronary angiography. Cardiovascular Research, 35(1), 120-124.https://doi.org/10.1016/S0008-6363(97)00090-4
Paik, J. M., Golabi, P., Younossi, Y., Srishord, M., Mishra, A., & Younossi, Z. M. (2020). The growing burden of disability related to nonalcoholic fatty liver disease: data from the global burden of disease 2007‐2017. Hepatology communications, 4(12), 1769-1780. https://doi.org/10.1002/hep4.1599
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, J., Xiao, J.-Z., Cao, H.-B., Liu, P.-A., Jiang, X.-G., Jiang, Y.-Y., Wang, J.-P., Zheng, H., Zhang, H., Bennett, P. H., & Howard, B. V. (1997). Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes care, 20(4), 537-544. https://doi.org/10.2337/diacare.20.4.537
Pan, W., Zhang, H., Wang, L., Zhu, T., Chen, B., & Fan, J. (2019). Association between Helicobacter pylori infection and kidney damage in patients with peptic ulcer. Renal failure, 41(1), 1028-1034.https://doi.org/10.1080/0886022X.2019.1683029
Pasceri, V., Cammarota, G., Patti, G., Cuoco, L., Gasbarrini, A., Grillo, R. L., Fedeli, G., Gasbarrini, G., & Maseri, A. (1998). Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation, 97(17), 1675-1679. https://doi.org/10.1161/01.CIR.97.17.1675
Pellicano, R., Ianiro, G., Fagoonee, S., Settanni, C. R., & Gasbarrini, A. (2020). Extragastric diseases and Helicobacter pylori. Helicobacter, 25, e12741.https://doi.org/10.1111/hel.12741
Polyzos, S. A., Kountouras, J., Papatheodorou, A., Patsiaoura, K., Katsiki, E., Zafeiriadou, E., Zavos, C., Anastasiadou, K., & Terpos, E. (2013). Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism, 62(1), 121-126. https://doi.org/10.1016/j.metabol.2012.06.007
Qu, X. H., Huang, X. L., Xiong, P., Zhu, C. Y., Huang, Y. L., Lu, L. G., Sun, X., Rong, L., Zhong, L., Sun, D. Y., Lin, H., Cai, M. C., Chen, Z. W., Hu, B., Wu, L. M., Jiang, Y. B., & Yan, W. L. (2010).Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World journal of gastroenterology: WJG, 16(7), 886-896.
Reaven, G. M. (1988). Role of insulin resistance in human disease. Diabetes, 37(12), 1595-1607. https://doi.org/10.2337/diab.37.12.1595
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M., Anstee, Q. M., Arab, J.P., Arrese, M., Bataller, R., Beuers, U., Boursier, J., Bugianesi, E., Byrne, C.D., Narro, G.E.C., Chowdhury, A., Cortez-Pinto, H.,...& NAFLD Nomenclature Consensus Group. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 78(6), 1966-1986. https://doi.org/10.1097/hep.0000000000000520
Sanyal, A. J., Foucquier, J., Younossi, Z. M., Harrison, S. A., Newsome, P. N., Chan, W. K., Yilmaz, Y., Ledinghen, V.D., Costentin, C., Zheng., M.H., Wong, V. W. S., Elkhashab, M., Huss, R. S., Myers, R.P., Roux, M., Labourdette, A., Destro, M., Poizat, C.F., Miette, M.,..., & Boursier, J. (2023). Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. Journal of hepatology, 78(2), 247-259. https://doi.org/10.1016/j.jhep.2022.10.034
Shin, S. P., Bang, C. S., Lee, J. J., & Baik, G. H. (2019). Helicobacter pylori infection in patients with chronic kidney disease: a systematic review and meta-analysis. Gut and liver, 13(6), 628. doi: 10.5009/gnl18517.
Sterling, R. K. (2006). FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients. Hepatology, 44(3), 769-770. DOI: 10.1002/hep.21333
Stefano, K., Federica, G., Marco, M., Roberta, M., Giorgio, N., Antonio, N., Gioacchino, L., Francesco, D. M., & Gian, L. D. A. (2018). Inverse association between Helicobacter pylori and inflammatory bowel disease: myth or fact?. Acta Bio Medica: Atenei Parmensis, 89(Suppl 9), 81-86. https://doi.org/10.23750%2Fabm.v89i9-S.7878
Sticlaru, L., Stăniceanu, F., Cioplea, M., Nichita, L., Bastian, A., Micu, G., & Popp, C. (2019). Dangerous liaison: helicobacter pylori, ganglionitis, and myenteric gastric neurons: a histopathological study. Analytical Cellular Pathology, 2019(1), 3085181. https://doi.org/10.1155/2019/3085181
Tang, D. M., Chascsa, D. M., Chou, J. Y., Ho, N., Auh, S., Wank, S. A., Koh, C., & Kumar, S. (2019). Helicobacter pylori infection is strongly associated with metabolic syndrome, and weakly associated with non‐alcoholic fatty liver disease, in a US Hispanic population. GastroHep, 1(6), 325-331. https://doi.org/10.1002/ygh2.375
Upala, S., Jaruvongvanich, V., Riangwiwat, T., Jaruvongvanich, S., & Sanguankeo, A. (2016). Association between Helicobacter pylori infection and metabolic syndrome: a systematic review and meta‐analysis. Journal of digestive diseases, 17(7), 433-440. https://doi.org/10.1111/1751-2980.12367
Wang, Y. C., Lin, T. Y., Shang, S. T., Chen, H. J., Kao, C. H., Wu, C. C., & Yang, T. Y. (2017). Helicobacter pylori infection increases the risk of adult-onset asthma: a nationwide cohort study. European Journal of Clinical Microbiology & Infectious Diseases, 36(9), 1587-1594. https://doi.org/10.1007/s10096-017-2972-1
Wijarnpreecha, K., Thongprayoon, C., Nissaisorakarn, P., Jaruvongvanich, V., Nakkala, K., Rajapakse, R., & Cheungpasitporn, W. (2017). Association of Helicobacter pylori with chronic kidney diseases: a meta-analysis. Digestive diseases and sciences, 62, 2045-2052. https://doi.org/10.1007/s10620-017-4516-z

Wong, V. W. S., Chan, W. K., Chitturi, S., Chawla, Y., Dan, Y. Y., Duseja, A., Fan, J., Goh,K. L., Hamaguchi,M., Hashimoto, E., Kim, S. U., Lesmana, L.A., Lin, Y.C., Liu, C.J., Ni, Y.H., Sollano, J., Wong, S. K. H., Wong, G. L. H., Chan, H.L.Y.,& Farrell, G. (2018). Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—part 1: definition, risk factors and assessment. Journal of gastroenterology and hepatology, 33(1), 70-85. https://doi.org/10.1111/jgh.13857
Wu, C. Y., Wu, C. H., Wu, M. S., Wang, C. B., Cheng, J. S., Kuo, K. N., & Lin, J. T. (2009). A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with H pylori eradication and proton pump inhibitor use. Clinical Gastroenterology and Hepatology, 7(4), 427-431. https://doi.org/10.1016/j.cgh.2008.12.029
Xiao, Q. Y., Wang, R. L., Wu, H. J., Kuang, W. B., Meng, W. W., & Cheng, Z. (2024). Effect of Helicobacter Pylori Infection on Glucose Metabolism, Lipid Metabolism and Inflammatory Cytokines in Nonalcoholic Fatty Liver Disease Patients. Journal of Multidisciplinary Healthcare, 1127-1135. https://doi.org/10.2147/JMDH.S453429
Yu, M., Zhang, R., Ni, P., Chen, S., & Duan, G. (2019). Helicobacter pylori infection and psoriasis: a systematic review and meta-analysis. Medicina, 55(10), 645. https://doi.org/10.3390/medicina55100645
Yu, Y. Y., Tong, Y. L., Wu, L. Y., & Yu, X. Y. (2022). Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial. Scientific Reports, 12(1), 19530. https://doi.org/10.1038/s41598-022-23746-0
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 77(4), 1335-1347. https://doi.org/10.1097/hep.0000000000000004
Zamani, M., Ebrahimtabar, F., Zamani, V., Miller, W. H., Alizadeh‐Navaei, R., Shokri‐Shirvani, J., & Derakhshan, M. H. (2018). Systematic review with meta‐analysis: the worldwide prevalence of Helicobacter pylori infection. Alimentary pharmacology & therapeutics, 47(7), 868-876. https://doi.org/10.1111/apt.14561
Zhou, B. G., Yang, H. J., Xu, W., Wang, K., Guo, P., & Ai, Y. W. (2019). Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systematic review and meta‐analysis of observational studies. Helicobacter, 24(3), e12576.https://doi.org/10.1111/hel.12576
Zhang, X., Gregg, E. W., Williamson, D. F., Barker, L. E., Thomas, W., Bullard, K. M., Imperatore, G., Williams, D. E., & Albright, A. L. (2010). A1C level and future risk of diabetes: a systematic review. Diabetes care, 33(7), 1665-1673. https://doi.org/10.2337/dc09-1939
Zimmet, P., Alberti, K. G. M., & Ríos, M. S. (2005). A new International Diabetes Federation (IDF) worldwide definition of the metabolic syndrome: the rationale and the results. Revista Española de Cardiología (English Edition), 58(12), 1371-1375. https://www.academia.edu/download/84783256/index.pdf
Zuo, Z. T., Ma, Y., Sun, Y., Bai, C. Q., Ling, C. H., & Yuan, F. L. (2021). The protective effects of Helicobacter pylori infection on allergic asthma. International Archives of Allergy and Immunology, 182(1), 53-64. https://doi.org/10.1159/000508330